Biogen Bets $1.5B on Failed Depression Drug; New Moms Suffering During COVID

(MedPage Today) -- Biogen is gambling $1.5 billion that Sage Therapeutics' investigational depression treatment zuranolone (SAGE-217) is approvable despite having flopped in a phase III trial last year. (FierceBiotech)
Underweight patients had...